← back to search

Sheng F. Cai

New York Proton Center · US
🔎 Find collaborators in Hematology · Molecular Biology →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Hematology · Molecular Biology
Research interest
Research interests include Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Histone Deacetylase Inhibitors Research, and Multiple Myeloma Research and Treatments.
h-index
24
citations
3,529
works
161
NIH funding
primary concept
Medicine
email

Recent publications

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed <i>NPM1</i> -Mutated or <i>KMT2A</i> -Rearranged AML
Journal of Clinical Oncology 2025cited by 26position: middledoi
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia
Cell stem cell 2025cited by 14position: middledoi
Exercise and Nutrition to Improve Cancer Treatment-Related Outcomes (ENICTO)
JNCI Journal of the National Cancer Institute 2024cited by 24position: middledoi
MEN1 mutations mediate clinical resistance to menin inhibition
Nature 2023cited by 234position: lastdoi
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed <i>IDH2</i>-mutant AML
Blood Advances 2023cited by 22position: firstdoi
BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation
Blood 2022cited by 33position: middledoi
Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia
American Journal of Hematology 2022cited by 24position: middledoi
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance
Cancer Discovery 2022cited by 19position: middledoi
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Blood Advances 2021cited by 187position: middledoi
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Leukemia & lymphoma/Leukemia and lymphoma 2021cited by 43position: middledoi
Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition
Cancer Discovery 2020cited by 43position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Ross L. Levine · Leukemia and Lymphoma Society2 papers (2021–2022)Wenbin Xiao · Kettering Medical Center2 papers (2021–2022)Andriy Derkach · Zhytomyr Polytechnic State University2 papers (2021–2022)Ying Liu · Biogen (United States)1 papers (2022–2022)Martin S. Tallman · Midwestern University1 papers (2021–2021)Timour Baslan · University of Pennsylvania1 papers (2022–2022)Troy Z. Horvat · Memorial Sloan Kettering Cancer Center1 papers (2021–2021)Kristian Helin · Institute of Cancer Research1 papers (2022–2022)Maximilian Stahl · Yale University1 papers (2021–2021) · 1 papers (2022–2022) · 1 papers (2022–2022)Scott W. Lowe · Memorial Sloan Kettering Cancer Center1 papers (2022–2022)Omar Abdel‐Wahab · Presbyterian Hospital1 papers (2021–2021)Hua Wang · Guangzhou University of Chinese Medicine1 papers (2022–2022) · 1 papers (2022–2022)Jacob L. Glass · Memorial Sloan Kettering Cancer Center1 papers (2021–2021)Aaron D. Viny · NewYork–Presbyterian Hospital1 papers (2021–2021)Charles G. Mullighan · Dana-Farber Cancer Institute1 papers (2022–2022)Anthony F. Daniyan · Memorial Sloan Kettering Cancer Center1 papers (2021–2021)Kamal Menghrajani · Icahn School of Medicine at Mount Sinai1 papers (2021–2021)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Hematology · Molecular Biology →